Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 8:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 8,250 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Humans Clear all
Completed Phase 1 Interventional

Intrathecal Administration of DUOC-01 in Adults With Primary Progressive Multiple Sclerosis

NCT04943289
View directory record Official record
Conditions
Primary Progressive Multiple Sclerosis
Interventions
DUOC-01
Biological
Lead sponsor
Joanne Kurtzberg, MD
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 30, 2026, 8:23 PM EDT
Active, not recruiting Not applicable Interventional

Neurophysiologically Based Brain State Tracking and Modulation in Focal Epilepsy

NCT03946618
View directory record Official record
Conditions
Epilepsy
Interventions
Medtronic Summit System, Olympus
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 30, 2026, 8:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Brain Health Together: Development and Pilot Test

NCT06914947
View directory record Official record
Conditions
Cognitive Impairment, Subjective Cognitive Decline, Mild Cognitive Impairment (MCI)
Interventions
Brain Health Together
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
65 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Oct 30, 2026, 8:23 PM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated Human Immunodeficiency Virus (HIV-1) Infected Controllers

NCT03060447
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Vesatolimod, Placebo, ART
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Ft. Pierce, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Oct 30, 2026, 8:23 PM EDT
Completed Phase 2 Interventional

A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS With or Without COPEGUS in Patients With Chronic Hepatitis C (CHC) Genotype 1 Infection.

NCT00377182
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Copegus, PEGASYS, RO5024048 1500mg, RO5024048 3000mg
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
17
States / cities
La Jolla, California • Long Beach, California • Sacramento, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 30, 2026, 8:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Mobile Enhanced Prevention Support for People Leaving Jail

NCT04036396
View directory record Official record
Conditions
HIV Infections, Sexually Transmitted Diseases, Bacterial, Hepatitis C, Substance Use Disorders
Interventions
Mobile Enhanced Prevention Support, Usual Care plus Customized Referrals
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 49 Years · Male only
Enrollment
233 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
3
States / cities
Los Angeles, California • Santa Fe Springs, California
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 30, 2026, 8:23 PM EDT
Recruiting Phase 4 Interventional

Zopa Retreatment and Vector Shedding in Adults With RRP

NCT06538480
View directory record Official record
Conditions
Recurrent Respiratory Papillomatosis, Papillomavirus Infection, Papillomaviridae
Interventions
Zopapogene imadenovec (Zopa)
Drug
Lead sponsor
Precigen, Inc
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Atlanta, Georgia • Bethesda, Maryland • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 30, 2026, 8:23 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Comparison of the Safety, PD and PK of a Single Dose of SYN023 Administered With Licensed Rabies Vaccines

NCT02956746
View directory record Official record
Conditions
Human Rabies
Interventions
SYN023, Imovax, RabAvert, HyperRAB ST (human rabies immune globulin)
Biological
Lead sponsor
Synermore Biologics Co., Ltd.
Industry
Eligibility
18 Years to 50 Years
Enrollment
164 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 27, 2019 · Synced Oct 30, 2026, 8:23 PM EDT
Withdrawn Phase 1 Interventional

A Study of the Pharmacology of Oseltamivir (Tamiflu) in Pregnancy

NCT00873886
View directory record Official record
Conditions
Pregnancy, Influenza
Interventions
Oseltamivir (Tamiflu), Blood Draws
Drug · Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 29, 2015 · Synced Oct 30, 2026, 8:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Modernization of in vivo-in Vitro Oral Bioperformance Prediction and Assessment

NCT02806869
View directory record Official record
Conditions
Human Gastrointestinal Physiology Data
Interventions
Single dose of ibuprofen (800 mg tablet), Pulmocare, two 8.0 oz (236.6 mL) cans
Drug · Dietary Supplement
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 8, 2017 · Synced Oct 30, 2026, 8:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Longitudinal Study of the Human Intestinal Microbiome

NCT00832286
View directory record Official record
Conditions
Dysbacteriosis
Interventions
Ciprofloxacin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Oct 30, 2026, 8:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

To Compare the Ischemic Pre-conditioning and Post-conditioning on Reperfusion Injury in Humans.

NCT00385151
View directory record Official record
Conditions
Endothelial Dysfunction
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
15 Years to 35 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Oct 30, 2026, 8:23 PM EDT
Terminated Phase 1Phase 2 Interventional

Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides

NCT00052377
View directory record Official record
Conditions
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Mycosis Fungoides/Sezary Syndrome, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage II Mycosis Fungoides/Sezary Syndrome, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome
Interventions
aldesleukin, recombinant interleukin-12, laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 30, 2026, 8:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Free Fatty Acids: Threshold Repeatability Study

NCT01550120
View directory record Official record
Conditions
Taste, Non-esterified Fatty Acids
Interventions
Not listed
Lead sponsor
Purdue University
Other
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Oct 30, 2026, 8:23 PM EDT
Completed Phase 1 Interventional Results available

Genomic Responses of Human Immune and Non-Immune Cells to Glucocorticoids

NCT02798523
View directory record Official record
Conditions
Normal Physiology
Interventions
Methylprednisolone sodium succinate(Solu-Medrol), Topical methylprednisolone (Advantan emulsion 0 /1%)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 30, 2026, 8:23 PM EDT
Withdrawn Not applicable Interventional

Feasibility of Adaptive Radiation Therapy for Human-papilloma Virus-positive Oropharyngeal Cancer Patients on MRIdian Linac

NCT05849142
View directory record Official record
Conditions
Oropharynx Cancer
Interventions
MRIdian Linac
Device
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 30, 2026, 8:23 PM EDT
Completed No phase listed Observational

A Study of Real-world Outcomes Among Patients Treated With Ribociclib

NCT07148505
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 30, 2026, 8:23 PM EDT
Recruiting Phase 1Phase 2 Interventional

First-in-human Study of UX016 in GNEM

NCT07511556
View directory record Official record
Conditions
GNE Myopathy
Interventions
UX016, Placebo
Drug · Other
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Orange, California • Iselin, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 30, 2026, 8:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

FTIH of ECC5004 in Healthy and Diabetic Participants

NCT05654831
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Placebo, ECC5004
Drug
Lead sponsor
Eccogene
Industry
Eligibility
18 Years to 70 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Oct 30, 2026, 8:23 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Inactivated, Split-Virion Influenza Vaccine and Standard Fluzone® Vaccine in Adult and Elderly Subjects

NCT00551031
View directory record Official record
Conditions
Influenza, Myxovirus Infection
Interventions
Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 1), Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 2), Split, Inactivated, Trivalent Influenza Vaccine (Standard dose), Split, Inactivated, Trivalent Influenza Vaccine (High-dose)
Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
2,098 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
29
States / cities
Alabaster, Alabama • Mobile, Alabama • Chandler, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Oct 30, 2026, 8:23 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of Circular RNA Treatment in Patients With Radiation Induced Xerostomia-1

NCT06714253
View directory record Official record
Conditions
Radiation-Induced Xerostomia and Hyposalivation
Interventions
RXRG001, Placebo
Biological
Lead sponsor
RiboX Therapeutics Ltd.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Palo Alto, California • Iowa City, Iowa • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 30, 2026, 8:23 PM EDT
Completed No phase listed Observational

Association Between Hepatitis C Infection and Renal Cell Carcinoma

NCT01405183
View directory record Official record
Conditions
Hepatitis C, Renal Cell Carcinoma, Colorectal Cancer
Interventions
Hepatitis C testing
Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 17, 2014 · Synced Oct 30, 2026, 8:23 PM EDT
Terminated Phase 1 Interventional

Study of ASN003 in Subjects With Advanced Solid Tumors

NCT02961283
View directory record Official record
Conditions
Neoplasms, Melanoma, Colorectal Neoplasm, Carcinoma, Non-small Cell Lung
Interventions
ASN003 ascending doses, ASN003 MTD
Drug
Lead sponsor
Asana BioSciences
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
5
States / cities
Los Angeles, California • Tampa, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 30, 2026, 8:23 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Repeat Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects

NCT02289495
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK2838232, Placebo, Ritonavir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 30, 2026, 8:23 PM EDT